SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM. It demonstrates greater than 850-fold selectivity versus all other known HDAC isozymes. This compound is capable of blocking multiple myeloma growth in vivo and acts as an anti-obesity agent in diet-induced obese mice.
- High selectivity for HDAC6
- Oral activity
- Non-hydroxamate nature
- Shown efficacy in blocking multiple myeloma growth in vivo
- Acts as an anti-obesity agent